FDA work integrity rises, survey says

Share this article:

A Union of Concerned Scientists survey of 997 FDA scientists suggests that agency leaders are helping to boost scientific integrity but still are beset by interference from special interests.

A UCS statement says the 2011 survey shows improvement over what FDA scientists reported in 2006. “Twenty-five percent more respondents, for example, now agree that FDA is acting effectively to protect public health,” it says.

“However, there is room for further improvement,” the statement adds. “FDA scientists express concern on several fronts, including their right to publish research and communicate with the public, the degree of corporate and political influence on regulatory decisions, and the overall transparency and accountability of the agency's decision-making.” Respondents also expressed a fear of retribution for sharing concerns about FDA and were unsure about their right to talk with the press.

FDA's response to the report was through a blog posting by agency chief scientist Jesse Goodman. “Preserving and protecting scientific integrity and working to promote an environment where all feel comfortable expressing their opinions and have confidence in the agency's decision-making must be an ongoing effort and part of our daily life and culture,” he writes.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?